Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma
Interventions: Bevacizumab, Electric Field Therapy, NovoTTF-200A Device, Quality-of-Life Assessment; Biological · Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 8
States / cities: Santa Monica, California • Miami, Florida • Atlanta, Georgia + 5 more

Conditions: Advanced Solid Tumors, Breast Cancer, Inflammatory Breast Cancer, Castleman's Disease, Multiple Myeloma
Interventions: CX-4945 oral formulation; Drug
Lead sponsor: Cylene Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 4
States / cities: Scottsdale, Arizona • Fort Collins, Colorado • Loveland, Colorado + 1 more

Conditions: Influenza A
Interventions: Pimodivir 600 mg, Placebo, SOC Treatment; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 13 Years to 85 Years
Enrollment: 553 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 140
States / cities: Birmingham, Alabama • Scottsboro, Alabama • California City, California + 105 more

Conditions: Major Depressive Disorder
Interventions: DVS SR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 283 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 35
States / cities: Birmingham, Alabama • Tucson, Arizona • Imperial, California + 28 more

Conditions: Alopecia
Interventions: 5% Minoxidil, 2% Minoxidil; Drug
Lead sponsor: Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 8
States / cities: Hot Springs, Arkansas • Minneapolis, Minnesota • Albuquerque, New Mexico + 4 more

Conditions: Ulcerative Colitis
Interventions: HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Agawam, Massachusetts

Conditions: Stable Atherothrombotic Disease
Interventions: CSL112 (reconstituted high density lipoprotein), Placebo; Biological
Lead sponsor: CSL Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 11
States / cities: Chula Vista, California • Jacksonville, Florida • Miami, Florida + 8 more

Conditions: Gout
Interventions: Rilonacept, Placebo, Allopurinol; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 74
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 71 more

Conditions: Cystic Fibrosis
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 3
States / cities: Birmingham, Alabama • Denver, Colorado • St Louis, Missouri

Conditions: Obesity and Overweight
Interventions: MET097, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,578 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 37
States / cities: Scottsdale, Arizona • Canoga Park, California • Oxnard, California + 33 more

Conditions: Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Interventions: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance, BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations; Drug
Lead sponsor: Bexion Pharmaceuticals, Inc.; Industry
Eligibility: 1 Year to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio

Conditions: Carcinoma, Pancreatic Ductal, Pancreatic Cancer, Pancreatic Disease
Interventions: AGS-1C4D4, Gemcitabine; Biological
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 15
States / cities: La Jolla, California • Boynton Beach, Florida • Miami, Florida + 12 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Diolamine, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Bladder Disease
Interventions: Bladder biopsy; Procedure
Lead sponsor: Tengion; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo; Drug
Lead sponsor: Othera Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 5
States / cities: Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more

Conditions: Aspirin-Associated Gastric Ulcers
Interventions: PA32540; Drug
Lead sponsor: POZEN; Industry
Eligibility: 55 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Ankle Sprain
Interventions: Diclofenac sodium topical gel 1%, Placebo; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 9
States / cities: Birmingham, Alabama • Aventura, Florida • Hialeah, Florida + 6 more

Conditions: Neurodegenerative Diseases, Osteoarthritis, Erectile Dysfunction, Autoimmune Diseases, Cardiomyopathies, Emphysema
Interventions: Administration of autologous adipose derived SVF; Procedure
Lead sponsor: Elliot Lander; Industry
Eligibility: 16 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rancho Mirage, California

Conditions: Angelman Syndrome
Interventions: minocycline; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 4 Years to 12 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Nocturia
Interventions: desmopressin acetate, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 799 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 70
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 59 more

Conditions: Alzheimer's Disease
Interventions: ABT-354, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • Overland Park, Kansas

Conditions: Breast Cancer, Brain Metastases
Interventions: ANG1005; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 19
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more

Conditions: Graft Vs Host Disease, Gastrointestinal Graft-Versus-Host Disease
Interventions: Oral beclomethasone dipropionate (drug); Drug
Lead sponsor: Enteron Pharmaceuticals; Industry
Eligibility: 0 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Sickle Cell Disease, Sickle Cell Anemia
Interventions: Hydroxyurea; Drug
Lead sponsor: Lifespan; Other
Eligibility: 6 Months to 21 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 13
States / cities: Phoenix, Arizona • Atlanta, Georgia • Peoria, Illinois + 9 more

Search by objective public record fields.

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Dose-escalation Study of Oral CX-4945

A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

A 6-Month Extension Study To The B2061032 Study To Evaluate The Safety, Tolerability, And Efficacy Of DVS SR In The Treatment Of Child And Adolescent Outpatients With MDD

Clinical Trial in Females With Female Pattern Hair Loss

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

A Single Ascending Dose Study Examining the Safety and Pharmacokinetic Profile of Reconstituted High Density Lipoprotein (CSL112) Administered to Patients

Study of the Safety and Efficacy of Long-Term Rilonacept Treatment for the Prevention of Gout Flares

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)

A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Multi Center Study to Obtain Bladder Tissue Specimens From Patients Undergoing Transurethral Resection Biopsy Procedure

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain

Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions

Minocycline in the Treatment of Angelman Syndrome

Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

Randomized Study of Oral Beclomethasone Dipropionate With Ten Days of Prednisone for Treatment of Gastrointestinal GVHD

Hydroxyurea Optimization Through Precision Study